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Summary Cells from two adenocarcinomas, an adenoma and a metastatic node were isolated in soft agar.
Expression of antigens, CEA, Y haptenic blood group and 791T-p72, defined by a range of candidate
antibodies for tumour targeting was assessed.
All of the cells expressed low levels of CEA but high levels of the Y haptenic blood group antigen although
there was enormous inter and intraclonal variation. Of particular interest was the membrane expression of
791T-p72 antigen on all of the dividing tumour cells as previous studies had shown that 791T/36 antibody
reacted with tumour stromal elements rather than malignant cell surfaces.
The DNA content was abnormal in all of the cells whether they were derived from diploid or aneuploid
primary tumours. They all grew readily in athymic mice and at least one monoclonal antibody, 791T/36,
localised efficiently within these xenografts.
Clonogenic cells therefore expressed the three tumour-associated antigens, several at higher levels than
observed in the primary tumour. Monoclonal antibody 'cocktails' should therefore allow antibody mediated
drug cytotoxicity to be effective at eradicating rapidly dividing tumour cells.
Colorectal carcinoma is one of the most common
malignant neoplasms, yet, in spite of significant
advances in surgical techniques, the survival rate
has not improved over the past two decades
(Silverberg, 1983; Stower & Hardcastle, 1985). The
major reasons are the advanced stage of the
majority of colorectal carcinomas at presentation
and that anticancer drugs have proven largely
ineffective against the disseminated disease
(Moertel, 1973).
Monoclonal antibodies recognising antigens
expressed selectively on human tumours are
currently being evaluated in this laboratory for
targeting conventional and novel anticancer drugs
and toxins to colorectal carcinoma (Garnett et al.,
1983; Pelham et al., 1983; Gallego et al., 1984).
However due to the heterogeneity of tumours
(Brattain et al., 1984; Edwards, 1985; Armitage et
al., 1984) it is essential to determine antigen
expression on the target colorectal tumour cells.
Overall tumour antigenicity has been studied on
disaggregated cells from primary tumours and on
cryopreserved tumour tissue sections (Finan et al.,
1982; Primus & Goldenberg, 1982; Durrant et al.,
1985). However as it is stem cells which maintain
the primary tumour and invade and seed in
metastatic sites (Steel, 1977) it is important to study
selectively their antigenicity. Any effective immuno-
therapy must be directed against the tumour stem
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cells if recurrence or dissemination of the primary
disease is to be prevented.
Cells have therefore been isolated from colorectal
tumours and their expression of antigens defined by
a range of candidate antibodies for tumour
targeting has been assessed. Proliferative capacity,
DNA content and tumourigenicity have also been
studied. All of the clones bound at least three
monoclonal antibodies although there was
considerable variation in the quantity and stability
of each antigen. They were all aneuploid and
formed tumours in athymic mice.
Materials and methods
Clinical specimens
Specimens from primary colorectal cancer and
infiltrated lymph nodes were obtained from
surgically resected specimens. Tumour cell
suspensions were prepared from tissue within 18h
of removal. Tissue was finely minced and placed in
0.05% collagenase (Boehringer, Mannheim, West
Germany) for 20min at 37°C with continuous
stirring. Tumour cells in suspension were removed
and washed three times in Hanks balanced salt
solution (HBSS). Fresh collagenase was added to
the remaining tissue and reincubated for a further
20min. This procedure was repeated twice before
combining the cells from all three dissociations and
resuspending them in Dulbecco medium containing
20% foetal calf serum (Gibco, Paisley, UK) and
designated 20F DMEM.
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Cell culture materials
The basal medium consisted of Dulbecco minimal
essential medium (DMEM) supplemented with
insulin (Sigma, Poole, Dorset, UK), gentamycin
(Nicholas Labs. Ltd., Slough, UK) and pyruvate
(Flow Labs., Irving, Fife, UK). DMEM was
enriched with 20% heat inactivated foetal calf
serum.
Primary culture andpassage
Five percent agar stock was prepared by dissolving
0.5g of bacterio Agar (Difco, Detroit, MA, USA)
in 10ml of sterile distilled water and autoclaving
for 15min at l5p.s.i.
Freshly disaggregated tumour cells (105) were
plated in 0.3% agar over an underlay of 0.5% agar,
both diluted with 20F DMEM, in a 24 well plate
(Costar, Cambridge, MA, USA). Cells were
incubated for 3-4 weeks at 37°C when large
colonies were observed. They were picked,
dispersed in 20F DMEM and plated into 24 well
plates. When they had formed confluent mono-
layers they were removed by vigorous pipetting and
transferred to flasks (Falcon, Becton Dickinson,
Oxnard, CA, USA). After several passages in flasks
it became necessary to use 0.25% trypsin/EDTA
(Flow, Irving, Fife, UK) to produce single cell
suspensions.
Cells in bulk culture were routinely passaged
twice weekly by detachment with 0.25%
trypsin/EDTA and reseeding in 25cm3 or 75cm3 T
flasks at - 106 cells. Plating efficiencies of the
proliferating cells were determined in soft agar as
described above but only 200 cells/well were plated
or by attachment of a similar number of cells to
1 ml plastic plates (Sterilin, Middlesex, UK). After
10-14 days agar colonies were counted microscopic-
ally and adherent colonies were fixed in 95%
methanol and stained with 0.1% crystal violet.
Doubling times were calculated by seeding cells at
104, 105, and 106ml-P in liquid culture and
counting the cell number daily for 10 days.
Monoclonal antibody reagents
A panel of three murine monoclonal antibodies was
used in this study. 791T/36 antibody recognises a
glycoprotein of mol.wt 72,000 which is found in
osteogenic sarcomas, colon carcinoma, lung
carcinoma, cervix carcinoma and prostate
carcinoma (Embleton et al., 1981; Price et al.,
1983). C14/1/46/40 antibody recognises a
difucosylated type 2 blood group antigen (Brown et
al., 1983). It is expressed on the majority of colon
adenocarcinomas and colon adenomas (Brown et
al., 1984). C24/1/39/11 antibody recognises an
epitope expressed on CEA and NCA (Price et al.,
1985).
Indirect immunofluorescence
Cells were stained by indirect immunofluorescence
(Durrant et al., 1984) and analysed on a FACS IV
(Becton Dickinson, Sunnyvale, CA, USA).
Fluorescein fluorescence was excited at 488nm and
collected via a 10nm band width band pass filter
centered at 515nm after adjustment for standard
conditions using fluorochrome labelled latex beads.
Fluorescence intensity is expressed as a mean
channel number (mean linear fluorescence - MLF),
calculated by multiplying the contents of each
channel by its channel number and dividing by the
total number of cells in the distribution (Roe et al.,
1985). Each cell line was also stained using normal
mouse Ig, and the MLF in this control was
subtracted from the values obtained with
monoclonal antibody. In order to determine
intraclonal variation 25% of the low and 25% of
the high fluorescing cells were excluded and the
range over which the remaining 50% of the cells
were distributed is defined. It was impossible to
define the standard deviation as the majority of
distributions were non Gaussian.
Karyotypic analysis
Two hours after addition of colcemid (0.5ygml-1;
Grand Island, Biological Co.) cells were removed
by vigorous pipetting and incubated in 0.075M KCI
at room temperature. Ten minutes later they were
fixed with 25% glacial acetic acid in anhydrous
methanol. Slides were stained with 10% Giemsa
(BDH, Poole, Dorset, UK) and the karyotypic
pattern determined by studying 50 metaphase
spreads.
DNA analysis
Cells were pelleted and resuspended in 50jl of
0.2% Triton X-100 (BDH, Dorset, UK) in 0.1M
NaCl at room temperature. After 1 min, 200,l of
mithramycin (93.1 jgml -1: Sigma, Dorset, UK)
and 200Il of ethidium bromide (37.5pgml-1:
Sigma, Dorset, UK) were added and incubated at
40C prior to analysis on a FACS IV. Fluorescence
was excited using 457nm light, and collected via
520nm long pass filters.
The DNA index was calculated as the ratio of
the mean relative DNA content of the GO1, cells of
the sample divided by the mean of the relative
DNA measurement of the diploid GO1, reference
cells. Cells with a normal diploid karyotype have by
definition a DNA index of 1.0.
Tumourigenicity
Six-to-ten-week-old female athymic mice (M/F,
MFI-nu/nu/Ola) were housed 6 mice/cage in an
isolator and fed autoclaved food and sterile tapANTIGENICITY OF CLONOGENIC CELLS 39
water ad libitum. Tumour xenografts were grown by
inoculating animals s.c. with 106-5 x 106
cells/0.2 ml. Tumours > 1 cm3 were noted.
Radiolabelling and xenograft localisation with
791T/36 antibody
Antibody 791T/36 was radiolabelled with 131I and
normal IgG2b with 1251I (Amersham International,
UK) to specific activities of -1 mCi (37MBq) mg 1.
Groups of mice with established tumour xenografts
were injected (i.p.) with 3/ig of each preparation.
Their drinking water was supplemented with 0.1%
Nal, and they were killed after four days and blood,
tumour and visceral organs and remaining carcass
counted for radioactivity.
For imaging of xenografts, 791T/36 antibody was
labelled with 11"In (Amersham International, UK)
to a specific activity of 1 mCi (37MBq)mg-1
(Perkins et al., 1985). Mice were injected (i.p.) with
40-80 Ci (2-4MBq) of 111In-antibody. Mice were
imaged 2 to 5 days later. Regions of interest were
drawn on the images around the whole body, the
xenograft site and a contralateral position and
count rates from each region used to calculate a
tumour to normal tissue (T:NT) ratio and the
percentage of whole body activity within the
tumour.
Results
Cells derived from 15 adenocarcinomas, two
adenomas and one metastatic lymph node were
plated in soft agar. Six of the adenocarcinomas, one
adenoma and the metastatic node grew producing
small colonies in agar with plating efficiencies
ranging from 0.02%-0.35%. Two of the cancers,
one adenoma and the metastatic node were
successfully transferred to culture flasks and
continue to grow vigorously 12 months later.
Pathological stages, DNA content, antigenicity and
clonogenicity of each colorectal tumour from
which these cultures were established are shown
in Table I.
Antigen expression
Binding of monoclonal antibodies, 791T/36,
C24/1/39/11 and C14/1/46/10 was studied in all of
the cells (Table II, Figure la-f).
Numerous colonies grew from the adenoma but
to ensure successful transfer to adherent growth
they were picked simultaneously and grown as a
single culture. They expressed a large quantity of
the Y haptenic blood group antigen, a significant
amount of the 791T-p72 but only a low level of
CEA/NCA (Table II). The expression of all 3
antigens decreased upon prolonged culture.
Several colonies grew from 168 primary
adenocarcinoma but only two continued to grow
when transferred to costar plates. One of these
clones bound a moderate level of C14/1/46/10 and
791T/36 but only a very small amount of
C24/1/39/11 in direct contrast to binding of these
monoclonal antibodies to the disaggregated cells of
the primary tumour (Table I). By passage 30 it
expressed all three antigens weakly and by passage
40 they had stopped dividing.
The metastatic node derived tumour cells from
patient 168 grew well in soft agar. Eight colonies
were picked and grown as independent clones, the
rest were pooled and grown simultaneously. This
Table I Human colorectal cancer tumours from which cultures were successfully
established
Patient No. C146 C168 C168(node) C170
Dukes stage adenoma C C C
(hepatic metastases)
DNA index 1.0 1.8 1.8 1.0
Antigen expression
MLF (rangea)
C24/1/39/11 ND 506(16-576) ND 37(16-140)
C14/1/46/10 ND 160(8-264) ND 753(16-1184)
791T/36 ND 72(16-90) ND 40(16-80)
Clonogenic assay
Plating efficiency 0.35 0.03 0.1 0.7
Adherent cultures
mass cultures 1 0 1 1
clones 0 2 8 12
'25% of the low and 25% of the high fluorescing cells were excluded. The range
defines the channels over which the remaining 50% of the cells were distributed
around the mean.40 L.G. DURRANT et al.
Table II Expression of CEA, CEA/NCA, a Y haptenic blood group determinant and
791T-p72 antigen as recognised by monoclonal antibodies C24/1/39/11, C14/1/46/10 and
791T/36 respectively in cells grown in vitro from primary tumours
Indirect immunofluorescence
C24/1/39/11 C14/1/46/10 791T/36
C146 MLF rangea MLF range MLF range
C146
mass culture 57 24-74 3242 2576-4080 377 144-512
C168
Primary tumour
Clone T, 310 210-376 247 112-376 ND ND
Clone T2 145 64-180 583 108-768 488 248-632
Infiltrated node
mass culture 84 34-110 693 32-976 160 84-392
Clone 1 172 32-208 612 144-832 322 88-392
Clone 2 172 48-200 859 144-2352 181 104-232
Clone 3 196 56-236 2195 256-2256 184 88-236
Clone 4 130 24-136 1229 304-1776 133 8-156
Clone 5 136 24-176 449 32-624 261 80-372
Clone 6 175 52-216 334 48-424 92 37-128
Clone 8 157 40-180 197 24-224 142 80-192
Clone 9 65 23-87 415 88-600 174 40-260
C170
mass culture 235 80-300 1530 1070-2001 268 176-356
Clone 1 161 48-204 872 112-1248 111 56-260
Clone 2 180 128-432 1598 272-2384 220 112-276
Clone 3 142 48-176 359 88-392 ND ND
Clone 4 132 72-184 308 120-280 106 58-132
Clone 5 207 56-264 1805 304-3152 110 60-136
Clone 6 193 72-236 832 240-1104 119 44-156
Clone 7 65 36-84 1353 1064-3584 171 68-216
Clone 8 62 30-78 2298 1184-3584 185 100-228
Clone 9 101 88-126 3516 3200-4080 153 70-220
Clone 10 171 74-228 2994 1872-4080 159 62-171
Clone 11 129 20-84 1169 112-1792 173 32-212
Clone 12 71 18-84 1864 768-2896 414 216-560
arange - 25% of the low and 25% of the high fluoresing cells were excluded. The range
defines the channel numbers over which the remaining 50% of the cells were distributed
around the mean.
multiclonal line expressed a large quantity of the
C14/1/46/10 defined antigen but only moderate
levels of CEA and 791T-p72 antigens. The clones
bound variable levels of C14/1/46/10 (MLF 197-
2195) which decreased on prolonged culture in two
of the clones, remained constant in two and
increased in four. Similar and low levels of
CEA/NCA was expressed in all of the clones (MLF
65-196); however, even this low expression had
decreased by passage 30. All of the clones expressed
791T-p72 antigen (MLF 92-322) but again its
expression was reduced by continuous culture.
Finally, 12 independent clones were picked and
grown from a second adenocarcinoma. The
remaining colonies growing in soft agar were
pooled and grown simultaneously. This multiclonal
line bound similar quantities of C14/1/46/10,
C24/1/39/11 and 791T/36 monoclonal antibodies as
observed in disaggregated cells from the primary
tumour (Table I). The clones expressed large
variations in C14/1/46/10 expression (MLF 308-
3516), but moderate levels of C24/1/39/11 (MLF
62-235) and 791T/36 (106-414). A gradual loss of
all 3 antigens was associated with passage number.
Figure 1 (a-f) illustrates the loss in antigen
expression between passages 3 and 30 for all of the
cell lines. There appeared to be a gradual normal-
isation of expression for all three antigens. There
was also enormous intraclonal variation in antigen
expression particularly for the C14/1/46/10 defined
epitope (Table II). This variation was apparent
even after only 3 in vitro passages and clearlyANTIGENICITY OF CLONOGENIC CELLS 41
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Figure 1 Expression of antigens as defined by the
monoclonal antibodies C14/l/46/10, C24/1/39/11 and
791T/36 in a series of colorectal cell lines derived from
primary tumours. a-c, expression at passage 3; d-f,
expression at passage 30; A, C146; A, C168 clones;
0, C170 clones.
demonstrates the inherent instability of dividing
tumour cells.
At passage 30 the most vigorously growing
cultures were chosen for more detailed analysis.
They are designated C146, C168 and C170.
Morphology
All the lines grew originally as volcanic clumps
densely packed at the centre with single layers of
cells at the extremities. However after several
passages they all exhibited cohesive monolayer
growth in liquid culture and formed densely packed
colonies where it was impossible to distinguish cell
borders in agar.
Growth rate andplating efficiencies
The cell lines C146, C168 and C170 have similar
doubling times of - 16, 25, 26h respectively (Table
III). All the lines also grew well in agar provided
they were supplied with 10% autologous
conditioned medium. Plating efficiencies in agar
ranged from 67-89% (Table III). Similar plating
efficiences were observed when the clonogenic cells
were plated at low density, i.e. 200 cells/plate in
liquid culture containing 10% autologous
conditioned medium (Table III).
Table III Growth characteristics of newly established
colorectal cell lines
C146 C168 C170
Doubling time (h) 16+1 25+2 26+0.5
Plating efficiencya
soft agar 73.9+9 67+9 89+4
liquid culture 72.0+0.05 58.5+0.05 87+3
DNA index 1.04 1.2 1.05
Karyotype
Mode 47 50 48
Frequency 20 25 50
Range 45-56 42-60 45-51
aPlating efficiency is defined as the number of colonies
divided by the number of cells plated.
DNA content
All of the cell lines had aneuploid chromosome
contents, C146 contained one extra chromosome,
C170 two and C168 four. These chromosome
perturbations were reflected in the relative DNA
indices although this level of resolution was at the
limits of the FACS IV cell sorter. The DNA
contents of these cell lines did not correlate with
the similar measurements on their primary tumours.
Tumours C146 and C170 were diploid with no
evidence of an aneuploid peak whereas tumour 168
contained a highly aneuploid population (DNA
index= 1.8) composed of 35% of the tumour cells.
Tumourigenicity
Each line formed xenografts in athymic mice from
s.c. inocula of 5 x 105 cells. It required 2-3 weeks to
form tumours of volume 1 cm3. Subsequent grafting
of these tumours into 8 mice took 2 weeks for
tumours of 1 cm3 to reform.
Xenograft tumours were resected following 2
passages in mice and disaggregated in 0.05%
collagenase and then analysed for antigenicity and
growth potential (Table IV). Similar levels of
antigen expression and DNA content were observed
in the xenograft derived cells to the corresponding
cells maintained in liquid culture. Slightly higher
doubling times were observed for all the xenograft
derived cells when they were originally re-
established in liquid culture but after several
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Table IV Biological characteristics ofcells grown in athymic mice
Number ofmice with Doubling time/ha Antigen expression/MLP
tumour after 30 daysl
Number ofmice given DNA Cultured Monoclonal Cultured
injection ofcells index Xenograft cells antibody Xenografts cells
C146 3/4 1.05 21+1 16+1 C14/1/46/10 1292+38 713+17
C24/1/39/11 61+18 61+18
791T/36 157+30 80+9
C168 3/4 1.2 23+2 25+2 C14/1/46/10 760+60 515+95
C24/1/39/11 30+ 10 60+9
791T/36 62+20 109+9
C170 3/4 1.05 27+1 26+0.5 C14/1/46/10 1169+201 763+28
C24/1/39/11 116+20 97+ 10
791T/36 111+6 92+29
aCells were injected into mice at passage 30, and analysed following 2 passages in mice or 32 passages in
culture.
passages they were indistinguishable from their
continuous culture counterparts.
Antibody localization in xenografts
Groups of mice with established xenografts were
injected (i.p.) with a mixture of 1311-791T/36 and
'25I-normal mouse IgG2b. Mice were killed after 4
days and blood, tumour and visceral organs
counted for radioactivity. There was preferential
accumulation of 1311-791T/36 in all three xenograft
lines (Figure 2a-c). The tissue to blood ratios of
1311 in the tumours for the three xenografts derived
from C146, C168 and C170 were 1.45:1, 1.01:1 and
1.96:1 compared to a maximum of 0.37:1, 0.36:1
and 0.45:1 respectively for any of the normal
organs. 125I normal IgG2b levels in the tumour
tissue were comparable to normal organs.
Localization indices calculated as the ratio of
tumour:blood ratio of 1311 antibody to
tumour: blood ratio of 1251 normal IgG2b were
3.0+0.2:1, 2.2+0.5:1 and 3.3+0.7:1 for lines 146,
168, 170 respectively.
Imaging of two mice with xenografts of the C170
tumour 2 to 5 days after injection of "'In-labelled
antibody showed clear localization of radioactivity
in tumours (Figure 3). Thus tumour to non-tumour
ratios of radioactivity of up to 4.6: 1 were achieved,
the counts in the tumour region being up to 18%
of those in the whole mouse.
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The term 'stem cell' describes a cell with the ability
to generate a large family of descendants within its
natural environment. These descendants can be
Figure 2 Localisation of 1311-labelled 791T/36 mono-
clonal antibody in colon carcinoma: C146(a), C168(b)
and C170(c) xenografts. C 1311; i, 1251.
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Figure 3 Imaging of two mice with C170 xenografts injected with IIn-labelled 791T/36 antibody. Mice A
and B with established tumours 1.5 and 1.8cm diameter were given 80 and 40yCi respectively of llIn-
791T/36 i.p. and imaged as shown. Tumour to non-tumour ratios of radioactivity on the images were 4.6:1
and 2.5:1 for mice A and B at 3 days and 5 days respectively, with 18% and 13% of the whole body counts
in regions of interest around the tumours.
either proliferating or non proliferating. The latter
are comprised of cells which have either irreversibly
lost the ability to divide and are lost naturally by
differentiation, exfoliation or death, or cells which
are non proliferating but can be stimulated to
divide in vivo. It is either this population or the
actively proliferating stem cells which are
responsible for regrowth of tumours after treatment
or for colonisation in different sites (Hamburger,
1981). Any effective therapy must therefore be
directed at these populations of cells. High growth
potential cells from colorectal tumours have
therefore been isolated in soft agar and the
expression of antigens recognised by monoclonal
antibodies of potential use in antibody mediated
drug therapy has been closely studied.
Disaggregated cells from two adenocarcinomas,
an infiltrated node and a benign adenoma grew
readily in soft agar and were transferred
successfully to monolayer culture. There was no
association between differentiation, DNA content,
site or Dukes stage and the ability to form colonies
in soft agar. The benign adenoma grew most
readily with a plating efficiency of 0.35%.44 L.G. DURRANT et al.
By passage 3 there were sufficient cells to stain
with the monoclonal antibodies and analyse on a
cell sorter. All of the cells bound high levels of
C14/1/46/10 but only low levels of C24/1/39/11.
There was an enormous interclonal heterogeneity
with MLFs for C14/1/46/10 ranging from 197-3516.
A rapid generation of intraclonal heterogeneity was
also observed suggesting that dividing tumour cells
have an enormous capacity for altering their
surface phenotype. The heterogeneity of human
colorectal cancer has been well documented
(Brattain et al., 1984). Studies on colorectal cell
lines have illustrated that this heterogeneity is also
observed in vitro (Brattain et al., 1984; Rosenthal et
al., 1977; Drewinko et al., 1984; Dexter et al.,
1981). The wide variation in antigen expression on
dividing cells from the same tumour implies that
this heterogeneity is also probably expressed at the
stem cell level although caution must be exerted at
extrapolating directly from dividing cells in vitro to
stem cells in vivo. Preferential regrowth of tumours
by stem cells expressing low antigen levels may
therefore occur following antibody mediated drug
cytotoxicity and emphasises the need for a 'cock-
tail' of monoclonal antibodies recognising non
associated antigens. There was no positive
correlation between expression of the three
monoclonal antibodies for any of the cells studied.
In fact, many cells which expressed low levels of
CEA expressed very high levels of the Y haptenic
blood group antigen.
Prolonged culture of the cells produced further
antigenic variation. Although in the majority of
clones this was due to a reduction in expression of
all 3 antigens, several clones showed enhanced
binding of C14/1/46/10 monoclonal antibody. A
similar drift in cell surface properties of tumour
cells in vitro was noted by Neri et al., (1981) and is
a problem when designing model systems for testing
the cytotoxicity of drug-antibody conjugates.
All of the cell lines had abnormal karyotypes
which were reflected in their DNA indices obtained
by flow cytometry. A similar observation was
described by Drewinko et al. (1984), who
subdivided colorectal cell lines on their DNA
content, morphological differentiation, tumouri-
genicity, growth in soft agar and in tissue culture
and on their levels of secreted CEA. Cell lines
C146 and C170 could be ascribed by similar
criteria to group I and C168 to group II. Growth
of cells with abnormal DNA contents from
tumours C146 and C170, which had diploid DNA
contents, was particularly interesting. The
clonogenic cells may all be aneuploid but comprise
such a small proportion of the whole tumour they
were undetected by the initial flow cytometric
analysis. The aneuploid stem cells may
preferentially grow in soft agar or short term tissue
culture may induce chromosomal abnormalities.
However, although 168 cells were aneuploid their
DNA index was less than observed for the primary
tumour suggesting that tissue culture may also
cause chromosome segregation.
As all of the clonogenic cells grew readily in
athymic mice without alteration in antigenicity and
at least one monoclonal antibody, 791T/36,
localised efficiently within these xenografts, they
should be a good model for studying in vivo effects
of drug-antibody conjugates.
It was surprising that an adenoma grew so
readily in soft agar and that the isolated clones
grew as vigorously as the carcinoma derived clones.
However, the ability of these cells to form tumours
in athymic mice and their aneuploid DNA content
suggests that the adenoma contained a small
malignant foci undetected histologically.
In the context of in vivo localisation of
monoclonal antibodies it has already been
established that radiolabelled 791T/36 antibody
localises in primary or metastatic human colorectal
tumours (Farrands et al., 1982; Armitage et al.,
1984), but the intratumoral site of production
and/or expression of the antigen was previously
poorly defined. As immunohistology with 791T/36
antibody showed reactions primarily in tumour
stromal elements and pseudoacini contents rather
than malignant cell surfaces (Armitage et al., 1983).
The present studies have demonstrated that the
antigen defined by 791T/36 monoclonal antibody is
produced by cells grown in vitro from colorectal
tumours. In addition the growth of these
clonogenic populations in nude mice provides
xenograft tumour models for experimental studies
on localisation of 791T/36 antibody for diagnostic
or therapeutic application.
This study therefore demonstrated that colorectal
tumours with high growth potential in vitro express
a range of tumour associated antigens, several at
higher levels than observed in the primary tumour.
Careful selection of monoclonal antibody 'cocktails'
should therefore allow antibody mediated drug
cytotoxicity to be effective at eradicating rapidly
dividing tumour cells.
These studies were supported by the Cancer Research
Campaign, UK. The skilful technical assistance of Mrs
R.A. Marksman and Mr 0. Roberts is gratefully
acknowledged.ANTIGENICITY OF CLONOGENIC CELLS 45
References
ARMITAGE, N.C., PIMM, M.V., BALDWIN, R.W. & HARD-
CASTLE, J.D. (1983). The pattern of antigen
distribution in colorectal tumours defined by
monoclonal antibodies. Br. J. Surg., 70, 691.
ARMITAGE, N.C., PERKINS, A.C., PIMM, M.V.,
FARRANDS, P.A., BALDWIN, R.W. & HARDCASTLE,
J.D. (1984). The localisation of an antitumour
monoclonal antibody (791T/36) in gastrointestinal
tumours. Br. J. Surg., 71, 407.
BRATTAIN, M.G., LEVINE, A.E., CHAKRABARTY, S.,
YEOMAN, L.C., WILLSON, J.K.V. & LONG, B. (1984).
Heterogeneity of human colon carcinoma. Cancer Met.
Rev., 3, 177.
BROWN, A., FEIZI, T., GOOI, H.C., EMBLETON, M.J.,
PICARD, J.K. & BALDWIN, R.W. (1983). A monoclonal
antibody against human colonic adenoma recognises a
difucosylated Type-2 blood group chains. Bioscience
Rep., 3, 163.
BROWN, A., ELLIS, I.O., EMBLETON, M.J., BALDWIN,
R.W., TURNER, D.R. & HARDCASTLE, J.D. (1984).
Immunohistochemical localization of Y hapten and the
structurally related H-type-2 blood group antigen on
large bowel tumours and normal adult tissues. Int. J.
Cancer, 33, 727.
DEXTER, D.L., SPREMULLI, E.N., FLIGIEL, Z., BARBOSA,
J.A., VOGEL, R., VAN VOORHEES, A. & CALABRESI, P.
(1981). Heterogeneity of cancer cells from a single
human colon carcinoma. Am. J. Med., 71, 949.
DREWINKO, B., YANG, L.Y., LEIBOVITZ, A., BARLOGIE,
B., LUTZ, D., JANSSON, B., STRAGAND, J.J. &
TRUJILLO, J.M. (1984). Cellular discriminants for a
biological classification of human colon carcinoma.
Cancer Res., 44, 4241.
DURRANT, L.G., PARKER, M., KENWORTHY, N. &
TAYLOR, G.M. (1984). Characterization of a human
mouse T cell hybridoma and identification of a clone
secreting and binding interleukin-2. Immunology, 52,
117.
DURRANT, L.G., ROBINS, R.A., ARMITAGE, N.C.,
BROWN, A., BALDWIN, R.W. & HARDCASTLE, J.D.
(1985). Association of antigen expression and DNA
ploidy in colorectal tumor. Cancer Res., (in press).
EMBLETON, M.J., GUNN, B., BYERS, V.S. & BALDWIN,
R.W. (1981). Antitumour reactions of monoclonal
antibody against a human osteogenic sarcoma cell line.
Br. J. Cancer, 43, 582.
EDWARDS, P.A.W. (1985). Heterogeneous expression of
cell surface antigens in normal epithelia and their
tumours, revealed by monoclonal antibodies. Br. J.
Cancer, 51, 149.
FARRANDS, P.A., PERKINS, A.C., PIMM, M.V., HARDY,
J.G., BALDWIN, R.W. & HARDCASTLE, J.D. (1982).
Radioimmunodetection of human colorectal cancers
using an anti-tumour monoclonal antibody. Lancet, [i,
397.
FINAN, P.J., GRANT, R.M., DE MATTOS, C. & 4 others.
(1982). Immunohistochemical techniques in the early
screening of monoclonal antibodies to human colonic
epithelium. Br. J. Cancer, 64, 9.
GALLEGO, J., PRICE, M.R. & BALDWIN, R.W. (1984).
Preparation of four daunomycin-monoclonal antibody
791T/36 conjugates with antitumour activity. Int. J.
Cancer, 33, 737.
GARNETT, M.C., EMBLETON, M.J., JACOBS, E., &
BALDWIN, R.W. (1983). Preparation and properties of
a drug-carrier-antibody conjugate showing selective
antibody-directed cytotoxicity in vitro. Int. J. Cancer,
31, 661.
HAMBURGER, A.W. (1981). Use of in vitro tests in
predictive cancer chemotherapy. J. Natl. Cancer Inst.,
66, 981.
MOERTEL, C.G. (1973). Cancer of the large bowel. In
Cancer Medicine, Trei and Holland (eds) p. 1597. Lea
and Febiger: Philadelphia.
NERI, A. & NICHOLSON, G.L. (1981). Phenotypic drift of
metastatic and cell surface properties of mammary
adenocarcinoma cell clones during growth in vitro. Int.
J. Cancer, 28, 731.
PELHAM, J.M., GRAY, J.D., FLANNERY, G.R., PIMM, M.V.
& BALDWIN, R.W. (1983). Interferon conjugation to
human osteogenic sarcoma monoclonal antibody
791T/36. Cancer Immunol. Immunother., 15, 210.
PERKINS, A.C., PIMM, M.V. & BIRCH, M.K. (1985). The
preparation and characterisation of 1'1In-labelled
791T/36 monoclonal antibody for tumour
immunoscintigraphy. Eur. J. Nucl. Med., (in press).
PRICE, M.R., CAMPBELL, D.G., ROBINS, R.A. &
BALDWIN, R.W. (1983). Characteristics of a cell
surface antigen defined by an anti-human osteogenic
sarcoma monoclonal antibody. Eur. J. Cancer Clin.
Oncol., 19, 81.
PRICE, M.R., BROWN, A., ARMITAGE, N.C.M. &
BALDWIN, R.W. (1985). Application of a micro radio-
immunoassay to analysis of monoclonal antibody
defined epitopes on antigen preparations from human
colonic cancer. IRCS Med. Sci., 13, 366.
PRIMUS, F.J. & GOLDENBERG, D.M. (1982). Functional
histopathology of cancer: a review of immunoenzyme
histochemistry. Methods Cancer Res., 20, 139.
ROE, R., ROBINS, R.A., LAXTON, R.R. & BALDWIN, R.W.
(1985). Kinetics of divalent monoclonal antibody
binding to tumour cell surface antigens using flow
cytometry: standardization and mathematical analysis.
Mol. Immunol., 22, 11.
ROSENTHAL, K.L., TOMPKINS, W.A.F., FRANK, G.L.,
McCULLOCH, P. & RAWLS, W.E. (1977). Variants of a
human colon adenocarcinoma cell line which differs in
morphology and carcinomenbryonic antigen
production. Cancer Res., 37, 4024.
SILVERBERG, E. (1983). Cancer statistics. C. A. Canc. J.
Clin., 33, 9.
STEEL, G.G. (1977). Growth kinetics of tumours. p. 217.
Oxford University Press: London.
STOWER, M.J. & HARDCASTLE, J.D. (1985). The results of
115patientswithcolorectalcancertreated overan 8 year
period in one hospital. Eur. J. Surgical Oncol., 11, 119.